P5-Mouse Phenotyping
P5-小鼠表型分析
基本信息
- 批准号:8080387
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAcute Erythroblastic LeukemiaAddressAffectAgeAge-MonthsAgonistAmphetaminesAnimal ModelAnimalsAnisotropyAnteriorAntipsychotic AgentsAnxietyApomorphineAutopsyBehaviorBehavioralBiological ModelsBoxingBrainBrain regionCellsCellular biologyCognitiveCollaborationsComplexConsultationsCorpus striatum structureCoupledCyclic NucleotidesDevelopmentDopamineERBB2 geneEquilibriumEsthesiaEthylnitrosoureaEtiologyEvaluationEvolutionExposure toG-substrateGTP-Binding ProteinsGelsolinGene AbnormalityGene ExpressionGene ProteinsGenesGeneticGlutamate DecarboxylaseGlutamate ReceptorGrantHaloperidolHomologous GeneImageIndium-111IndividualKetamineKnock-outKnockout MiceLearningLocomotionMemoryMessenger RNAModelingModificationMolecularMotorMotor ActivityMusMutationMyelinMyelin Associated GlycoproteinMyelin ProteinsN-Methyl-D-Aspartate ReceptorsNeuroanatomyNeuronsOligodendrogliaParahippocampal GyrusPeripheralPersonsPharmaceutical PreparationsPhenotypePlayProteinsReagentReceptor SignalingReflex actionRegulationReportingResourcesRodent ModelRoleSchizophreniaScreening procedureSignal TransductionSocial InteractionSpecificitySpecimenStagingStructureSuperior temporal gyrusSynapsesSynapsin ITechniquesTestingTimeTransferrinUpdateViral OncogeneWorkbasebehavior influencebehavior testbrain tissuecingulate cortexgenetic associationin vivointerestlaser capture microdissectionmeetingsmolecular phenotypemouse modelmyelinationneurochemistryneuroimagingoligodendrocyte precursoroverexpressionphosphoric diester hydrolasepostsynaptic density proteinprecursor cellprepulse inhibitionprotein expressionputamenresearch studyresponsestereotypytranscription factorwhite matterworking groupyoung adult
项目摘要
This project is dedicated to the development and characterization of mouse model systems that best reflect
the myelin and oligodendrocyte related (OMR) gene expression deficits in persons with schizophrenia.
Several different genetically modified mouse model systems will be evaluated (e.g., Quaking, MAG,
PTPRZ1, and Olig2. Each of these mouse model systems will be screened for deficits in the expression of
OMR genes using a panel of OMR genes that we have shown to be differentially affected in schizophrenia.
Those that evidence gene expression deficits on at least 3 OMR genes known to be affected in
schizophrenia will then be assessed for behavioral deficits. The behavioral phenotyping test battery will
include screening tests of simple (e.g., reflexes, locomotion, balance, sensation) as well as complex
(learning, memory, startle, prepulse inhibition of startle, social interaction, anxiety) behaviors. Coupled with
these purely behavioral tests will be pharmacological probes to ascertain whether pharmacological profiles
commonly viewed as prototypical for rodent models of schizophrenia are also evidenced by the OMR gene
deficient mice. Once "best-fit" model systems have been identified, they will be studied longitudinally to
ascertain the evolution of gene expression and behavioral deficits from 3 months of age through to 18
months of age. In addition, laser capture microdissection techniques will be employed to investigate gene
expression in identified cell groups. In collaboration with Project 1, the "best-fit" mouse model system will be
systematically imaged by DTI in vivo at ages corresponding to those for behavioral testing. In collaboration
with Project 3, brain tissue specimens from additional mice will be studied for changes in oligodendroglial
proliferation, differentiation and survival. Significant progress has already been made in this regard. All of
the behavioral test paradigms have been piloted and parameters have been optimized for use in mice in our
phenotyping facility (results and descriptions appended). Three of the 4 animal model systems proposed for
use (Quaking, Olig2, and MAG) have been obtained. Some studies have already been completed in these
mice and colonies have been established to enable more large scale studies.
该项目致力于小鼠模型系统的开发和表征,
精神分裂症患者髓鞘和少突胶质细胞相关(OMR)基因表达缺陷。
将评估几种不同的遗传修饰小鼠模型系统(例如,震颤,MAG,
PTPRZ1和Olig2。将筛选这些小鼠模型系统中的每一个的以下表达缺陷:
OMR基因使用一组我们已经证明在精神分裂症中受到差异影响的OMR基因。
那些在至少3个已知受影响的OMR基因上证明基因表达缺陷的人,
精神分裂症将被评估为行为缺陷。行为表型测试组合将
包括简单(例如,反射,运动,平衡,感觉)以及复杂的
(学习、记忆、惊吓、惊吓前脉冲抑制、社会交往、焦虑)行为。加上
这些纯粹的行为测试将是药理学探针,以确定药理学特征是否
通常被视为精神分裂症啮齿动物模型的原型,也由OMR基因证明
缺陷小鼠一旦确定了“最适合”的模式系统,将对其进行纵向研究,
确定从3个月大到18岁的基因表达和行为缺陷的演变
月龄。此外,激光捕获显微切割技术将用于研究基因
在鉴定的细胞群中表达。在与项目1的合作中,“最适合”的鼠标模型系统将是
在对应于行为测试的年龄,通过DTI在体内系统地成像。合作
在项目3中,将研究来自其他小鼠的脑组织标本中少突胶质细胞的变化,
增殖、分化和存活。在这方面已经取得了重大进展。所有
在我们的研究中,已经对行为测试范例进行了试验,并对用于小鼠的参数进行了优化。
表型分析设施(随附结果和描述)。提出的4种动物模型系统中有3种
使用(Quaking,Olig2和MAG)。其中一些研究已经完成
已经建立了小鼠和群体以进行更大规模的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VAHRAM HAROUTUNIAN其他文献
VAHRAM HAROUTUNIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VAHRAM HAROUTUNIAN', 18)}}的其他基金
NIH BRAIN AND TISSUE RESPOSITORY (NBTR)
美国国立卫生研究院 (NIH) 脑和组织存储库 (NBTR)
- 批准号:
10916989 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
The adaptive-innate immune interactome across multiple tissues in Alzheimer's disease
阿尔茨海默病跨多个组织的适应性先天免疫相互作用组
- 批准号:
10662733 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Single-nucleus transcriptome profiling across multiple brain regions in Parkinson's Disease
帕金森病多个脑区的单核转录组分析
- 批准号:
10372330 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10302046 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10685326 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10495197 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer Disease
了解人脑免疫细胞在阿尔茨海默病中的保护和神经炎症作用
- 批准号:
10412322 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
THE PURPOSE OF THIS CONTRACT IS TO ESTABLISH COLLECTION SITES(S) (I.E., THE NIH BRAIN AND TISSUE REPOSITORY (NBTR)) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, PROCESS, STORE, CURATE, PRE
本合同的目的是建立收集站点(即 NIH 大脑和组织存储库 (NBTR)),以提供积极获取、接收、处理、存储、整理、预检的服务
- 批准号:
10473437 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
THE PURPOSE OF THIS CONTRACT IS TO ESTABLISH COLLECTION SITES(S) (I.E., THE NIH BRAIN AND TISSUE REPOSITORY (NBTR)) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, PROCESS, STORE, CURATE, PRE
本合同的目的是建立收集站点(即 NIH 大脑和组织存储库 (NBTR)),以提供积极获取、接收、处理、存储、整理、预检的服务
- 批准号:
10685914 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:














{{item.name}}会员




